EMA coordinates evaluation of medicinal products including radiopharmaceuticals across EU member states.
Centralized marketing authorization scientific advice and pharmacovigilance.
Works with national competent authorities for device and radiation matters.
Issues guidelines for clinical trials and quality of radiopharmaceuticals.
Molecular radiotherapy uses radiolabeled agents to treat disease. It delivers targeted radiation to tumors and other lesions. It combines diagnostic imaging with therapy planning.
Theranostic pairs match diagnostic tracers with therapeutic agents. Indications include neuroendocrine tumors and prostate cancer. Patient selection and dosimetry are critical for safety.
Imaging monitors distribution and response to therapy. Dosimetry guides treatment planning and follow up. Multidisciplinary teams coordinate care and manage toxicity.
New agents and delivery methods expand therapeutic options. Personalized dosimetry improves efficacy and safety. Research aims to broaden indications and access.
